Northwestern Mutual Wealth Management’s Citius Pharmaceuticals CTXR Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8	Buy	+8	New	+$6	﹤0.01%	4088

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northwestern Mutual Wealth Management's CTXR Position: Q1 2026 in Review

Northwestern Mutual Wealth Management opened a new position in Citius Pharmaceuticals (CTXR) in Q1 2026: 8 shares worth $8. The stake represents ﹤0.01% of the portfolio and ranks #4088 among its holdings.

38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Northwestern Mutual Wealth Management held 8 shares of Citius Pharmaceuticals worth $8 as of Q1 2026.
Citius Pharmaceuticals was a new Northwestern Mutual Wealth Management position in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #4088 holding.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.